


# What is MedTrait®?

MedTrait is a laboratory report and interpretation solution which combines pharmacogenetics, drug interactions, duplicate therapy awareness and lifestyle factors into a powerful medication and risk factor management platform, offering healthcare providers a tool for personalized medicine, leading to better patient outcomes.

MedTrait helps bridge the gap between complicated genetic data and clinical guidance, paving the way for better prescribing decisions - quickly and simply - in many areas of patient care including poly-pharmacy, pain management, mental health, cardiology, surgery, pediatrics, OB/GYN and more.

MedTrait is produced and delivered by PTC Labs, Inc. PTC Labs has over 22 years of clinical genetic experience as a leading company in the field. The MedTrait team includes experienced professionals maintaining the most powerful pharmacogenetic reporting platform available.



**GENETRAIT LABORATORIES MedTrait** Patient: John Doe Gender: M DOB: 04/20/1950

**MedTrait™ Report**

Patient	Provider	Specimen
<b>John Doe</b> M Age at time of report: 68 04/20/1950 Race: Caucasian	Doctor Physician, M.D., Ph.D. <b>First Test Medical</b> 300 Portland Suite 300 Columbia, MO 65201 (573) 442-9870	<b>Basal Swab</b> Thu Jul 27 2017 Fri Jul 28 2017 Mon May 14 2018 17960

**Contents**

Current Medication Report	2	Comprehensive Genetic Drug Panel	5
Duplicate Therapy Summary	3	Medication Guidance	11
Current Medication Summary	3	Genetic Summary	19
Risk Factor Assessment	4	This Report includes	20
Risk Factor Guidance	4	Legend	21

**Highlights**



*Based on the findings within this report, the following information should be closely reviewed.*

- Duplicate Therapy Considerations**  
 2 or more medications are indicated as prescribed for similar therapeutic intent. Please review the Duplicate Therapy section for further details.
- Medication Considerations**  
 Lopressor is indicated as higher risk / higher benefit for this patient. Plavix is indicated as lower risk / lower benefit for this patient. Please review the Current Medication Report and Current Medication Summary sections for further details.
- Genetic Considerations**  
 5 genetic groups have variants that affect drug metabolism, including CYP2D6 (PM), CYP2C19 (IM), VKORC1 (Medium Sensitivity to Warfarin), ATM (Increased Response), and APOE (Reduced Risk). Please review the Genetic Summary section for further details.

PTC Genetrait™ Laboratories, a Division of PTC Laboratories, Inc.  
 1000 University Drive, Columbia, MO 65201 USA  
 (573) 392-8648 | (573) 442-9870 Fax: (573) 392-8648  
 Copyright 2018 PTC Laboratories, Inc.

Ordering Provider: **First Test Medical** | Submission ID: **1707.00644** | Reported Date: **Mon May 14 2018** | Page: **1 of 21**

# MedTrait Advantages and Features

**GENETRAIT LABORATORIES MedTrait** Patient: John Doe Gender: M DOB: 04/20/1950

**MedTrait™ Report**

Patient	Provider	Specimen
<b>John Doe</b> M Age at time of report: 68 04/20/1950 Race: Caucasian	Doctor Physician, M.D., Ph.D. First Test Medical 300 Parkland Suite 300 Columbia, MO 65201 (573) 442-9870	<b>Basel Swab</b> Thu Jul 27 2017 Fri Jul 28 2017 Mon May 14 2018 17960

**Contents**

Current Medication Report	2	Comprehensive Genetic Drug Panel	5
Duplicate Therapy Summary	3	Medication Guidance	11
Current Medication Summary	3	Genetic Summary	19
Risk Factor Assessment	4	This Report includes	20
Risk Factor Guidance	4	Legend	21

**Highlights**

*Based on the findings within this report, the following information should be closely reviewed.*


- Duplicate Therapy Considerations**  
2 or more medications are indicated as prescribed for similar therapeutic intent. Please review the Duplicate Therapy section for further details.
- Medication Considerations**  
Lopressor is indicated as higher risk / higher benefit for this patient. Plavix is indicated as lower risk / lower benefit for this patient. Please review the Current Medication Report and Current Medication Summary sections for further details.
- Genetic Considerations**  
5 genetic groups have variants that affect drug metabolism, including CYP2D6 (PM), CYP2C19 (IM, VKORC1 (Medium Sensitivity to Warfarin), ATM (Increased Response), and APOE (Reduced Risk). Please review the Genetic Summary section for further details.

**PTC** Genetrait™ Laboratories, a Division of PTC Laboratories, Inc.  
 1000 Corporate Drive, Columbia, MO 65201 USA  
 (573) 392-8648 | (573) 442-9870 Fax: (573) 392-8648  
 Copyright 2018 PTC Laboratories, Inc.

Ordering Provider: First Test Medical | Submission ID: 1707.00644 | Reported Date: Mon May 14 2018 | Page: 1 of 21

# Quick, Actionable Guidance


Patient issues and solutions can be evaluated within seconds



- **Highlights on the first page**
  - At-a-glance alerts without digging through pages of the report
  - Answers the question "what do I need to know about?" within seconds
- **The "grid"**
  - Visualize current medications as at risk for side effects, ineffectiveness, or both, rather than a traditional linear "risk" ranking
- **Easy to interpret**
  - Modern styling and intuitive iconography make interpretations easy and impactful
  - Also designed for full utility in a gray-scale, low quality faxing situations

# Details Where It Matters


Reference details provided for current and future treatment guidance



- **Detailed recommendations and reference material**
  - Only the information needed and none of the extra, allowing the provider to find answers instantly
  - Answers for now, plus reference guide for the future
- **Layers of information**
  - At-a-glance answers when needed quickly
  - Details where they matter
  - References when appropriate
- **Interactive online app**
  - A MedTrait report also includes access to the interactive MedTrait online app for updating medications and evaluating alternatives in real time

# Strong Scientific Integrity


Laboratory guidance professionally curated



- **Scientific integrity**
  - Industry-leading attention to report interpretation quality
  - Genetic guidance is well researched, evidence level is provided, and references are well documented to confidently guide clinical utility
- **Multiple considerations**
  - Genetic interactions, drug interactions, lifestyle interactions and duplicate therapy are all considered when analyzing current medication regimen and alternatives
- **Smart alternative suggestions**
  - Alternative medications are considered based on patient's disease state (or most common use) when there may be better prescribing options available

# Limitless Customization

Reports built for the specific needs  
of the provider



- **Customization**
  - Report can be personalized in many different ways to match the specific needs of the provider and facility
- **Targeted and actionable**
  - Unique reports for unique care situations allows practitioners to access the most important information quickly and easily instead of adopting a one-size-fits-all solution



## For Help and Support • Contact the MedTrait Team

medtrait.net | ptclabs.com

genetrail@ptclabs.com • (573) 442-9948 phone • (573) 442-9870 fax

PTC Laboratories, Inc.  
300 Portland Street • Suite 300  
Columbia, MO 65201 USA